University of Pennsylvania

ScholarlyCommons
Statistics Papers

Wharton Faculty Research

2016

Instrumental Variables Estimation With Some Invalid Instruments
and its Application to Mendelian Randomization
Hyunseung Kang
University of Pennsylvania

Anru Zhang
University of Pennsylvania

Tony Cai
University of Pennsylvania

Dylan Small
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/statistics_papers
Part of the Physical Sciences and Mathematics Commons

Recommended Citation
Kang, H., Zhang, A., Cai, T., & Small, D. (2016). Instrumental Variables Estimation With Some Invalid
Instruments and its Application to Mendelian Randomization. Journal of the American Statistical
Association, 111 (513), 132-144. http://dx.doi.org/10.1080/01621459.2014.994705

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/statistics_papers/71
For more information, please contact repository@pobox.upenn.edu.

Instrumental Variables Estimation With Some Invalid Instruments and its
Application to Mendelian Randomization
Abstract
Instrumental variables have been widely used for estimating the causal effect between exposure and
outcome. Conventional estimation methods require complete knowledge about all the instruments’
validity; a valid instrument must not have a direct effect on the outcome and not be related to
unmeasured confounders. Often, this is impractical as highlighted by Mendelian randomization studies
where genetic markers are used as instruments and complete knowledge about instruments’ validity is
equivalent to complete knowledge about the involved genes’ functions.
In this paper, we propose a method for estimation of causal effects when this complete knowledge is
absent. It is shown that causal effects are identified and can be estimated as long as less than 50% of
instruments are invalid, without knowing which of the instruments are invalid. We also introduce
conditions for identification when the 50% threshold is violated. A fast penalized �1 estimation method,
called sisVIVE, is introduced for estimating the causal effect without knowing which instruments are valid,
with theoretical guarantees on its performance. The proposed method is demonstrated on simulated data
and a real Mendelian randomization study concerning the effect of body mass index on health-related
quality of life index. An R package sisVIVE is available on CRAN. Supplementary materials for this article
are available online

Keywords
Body mass index, causal inference, health-related quality of life, instrumental variable, �1 penalization,
pleiotropy

Disciplines
Physical Sciences and Mathematics

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/statistics_papers/71

Instrumental Variables Estimation With Some Invalid
Instruments and its Application to Mendelian
Randomization∗
Hyunseung Kang, Anru Zhang, T. Tony Cai, Dylan S. Small
Department of Statistics
The Wharton School
University of Pennsylvania

Abstract
Instrumental variables have been widely used for estimating the causal effect between exposure and outcome.

Conventional estimation methods require complete

knowledge about all the instruments’ validity; a valid instrument must not have a
direct effect on the outcome and not be related to unmeasured confounders. Often,
this is impractical as highlighted by Mendelian randomization studies where genetic
markers are used as instruments and complete knowledge about instruments’ validity
is equivalent to complete knowledge about the involved genes’ functions.
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In this paper, we propose a method for estimation of causal effects when this complete knowledge is absent. It is shown that causal effects are identified and can be
estimated as long as less than 50% of instruments are invalid, without knowing which
of the instruments are invalid. We also introduce conditions for identification when
the 50% threshold is violated. A fast penalized `1 estimation method, called sisVIVE,
is introduced for estimating the causal effect without knowing which instruments are
valid, with theoretical guarantees on its performance. The proposed method is demonstrated on simulated data and a real Mendelian randomization study concerning the
effect of body mass index on health-related quality of life index. An R package sisVIVE
is available on CRAN. Supplementary materials for this article are available online.

Keywords: Body mass index, causal inference, health-related quality of life, instrumental
variable, `1 penalization, pleiotropy.
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1

INTRODUCTION

Instrumental variables (IV) is a popular method for estimating the causal effect of an exposure on an outcome when there is unmeasured confounding. Conventional IV estimation
methods require that the instruments are valid, or informally speaking, that the instruments
are (A1) related to the exposure (A2) have no direct pathway to the outcome and (A3) are
not related to unmeasured variables that affect the exposure and the outcome (see Figure 1
and Section 2 for a formal definition of valid IVs). For example, Figure 1 is an illustration
of the IV assumptions and one potential violation of the IV assumptions(see Hernán and
Robins (2006) for details on other possible violations). Here, the IV is a genetic marker that
is a single nucleotide polymorphism whose value is fixed at birth and the unmeasured variables refer to variables that precede the assignment of the genetic marker, such as population
stratification (to be discussed later). The challenge in IV estimation is to find valid instruments that satisfy assumptions (A1)-(A3). Unfortunately, this is a difficult task, especially
in the case of Mendelian randomization (MR).
In MR, the goal is to estimate the causal effect of an exposure on an outcome by using
genetic markers, specifically single nucleotide polymorphisms (SNPs), as instruments (Davey
Smith and Ebrahim 2003, 2004; Lawlor et al. 2008; Wehby et al. 2008). For example,
Timpson et al. (2005) studied the causal effect of C-reactive protein (CRP), the exposure, on
various metabolic outcomes, such as body mass index (BMI) and cholesterol biomarkers (e.g.
tryglycerides), using four haplotypes constructed from three SNPs (rs1800947, rs1130864,
rs1205) as instruments. The instruments have been previously associated with plasma CRP
levels, thereby agreeing with (A1). However, agreement with (A2) and (A3) is less certain.
As the authors of the study noted, it is plausible that one or more of the genes that contain the
SNPs, rs1800947, rs1130864, and rs1205, may have multiple functions, known as pleiotropy,
where, in addition to changing CRP levels (the exposure), the gene containing one of these
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Figure 1: Diagram of One Possible Violation of Instrumental Variables Assumptions. Arrows represent associations between variables. Absence of arrows indicates no relationship.
Numbers (A1), (A2), and (A3) indicate different instrumental variables assumptions. In this
example, the unmeasured variable refers to variables that precede the assignment of the genetic marker, such as population stratification, and the genetic marker is a single nucleotide
polymorphism whose value is fixed at birth. As such, the arrows from the unmeasured variable originate from the unmeasured variable and the arrow from the genetic marker goes
from it to the outcome (A2) since the genetic marker is fixed at the time of conception.
SNPs would change triglyceride levels or BMI (the outcome) and (A2) would not hold.
Indeed, recent work by Martı́nez-Calleja et al. (2012) suggested that one of the instruments
used, rs1130864, is directly linked to BMI, one of the outcomes, raising doubts about causal
estimates when this SNP is assumed to be a valid instrument.
As another example, Katan (1986), in one of the first discussions of MR, proposed to
estimate the causal effect of serum cholesterol level on cancer by using the apolipoprotein
E polymorphism (APOE)’s effect on serum cholesterol levels. However, as Davey Smith
and Ebrahim (2004) argued, the current knowledge about the APOE gene and its multiple
pleiotropic effects on longevity, cholesterol biomarkers, and several other variables, would
invalidate the APOE gene as a valid instrument, specifically due to its violation of (A2), and
make an IV analysis based on it biased.
Both examples highlight a fundamental limitation with MR studies. For one, pleiotropy
and its impact on (A2) is a concern in most MR studies (Little and Khoury 2003; Davey
Smith and Ebrahim 2003, 2004; Thomas and Conti 2004; Brennan 2004; Lawlor et al. 2008).
4

Lawlor et al. (2008) also list other biological phenomena associated with genetic instruments
such as linkage disequilibrium and population stratification that may violate (A2) and (A3).
Unfortunately, verifying genetic instruments as valid IVs requires having complete knowledge
of the instruments’ biological function and pleoitropic effects. As both examples highlight,
the biological understanding of many genetic markers and their potential pleiotropic effects
are typically incomplete at the time of the study (Solovieff et al. 2013). In the face of
incomplete biological knowledge and possible instrument invalidity, can valid causal estimates
be derived?
Previous work in IV estimation in the presence of possibly invalid instruments is limited.
Traditional instrumental variables literature has stated that to estimate the causal effect of
an exposure on an outcome when there are unmeasured confounders, one needs to have at
least one instrument that one knows is valid (Wooldridge 2010). Andrews (1999) considered the invalid instrument case in the general context of generalized method of moments
(GMM) estimation common in econometrics and arrived at an identification result that is
similar to our identification result in Theorem 1. The author also proposed an estimation
strategy, called the moment selection criteria (MSC), to correctly select the valid instruments, which is similar to (8) in Section 3.2. Unfortunately, as we discuss in Section 3.2,
MSC is computationally infeasible when the number of instruments are large. Kolesár et al.
(2011) considered the possibility of identifying causal effects when all the instruments are
invalid because of direct effects on the outcome. The authors showed that if the direct effects are orthogonal to the instruments’ effects on the treatment, then the causal effect can
be identified. Kolesár et al. (2011) describes conditions under which this orthogonality is
plausible. But, for MR, this stringent structure on the instruments would not hold in most
cases as it would mean that the pleiotropic effects of the IVs are orthogonal to the effects
of the IVs on the treatment. Gautier and Tsybakov (2011) analyzed instrumental variables
regression in the presence of possibly invalid instruments. However, for their procedure to
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work, one must have a pre-defined set of known valid instruments. Finally, Mealli and Pacini
(2013) explored how using an auxiliary outcome can tighten bounds or provide identification
of the effect of a treatment on a primary outcome when there is only one binary instrument
that may violate (A2) by using an using auxiliary outcome. However, their work is different
to our problem where we consider multiple candidate instruments.
Our paper adds to the prior literature as follows. First, we show that it is indeed possible
to identify and estimate the causal effect without a known pre-defined set of valid instruments. In particular, under a weaker condition where the proportion of invalid instruments
is strictly less than 50% of the total instruments, we show that identification and estimation
is possible. For example, given four possible haplotypes/instruments in the previous example
by Timpson et al. (2005), estimation of the causal effect of CRP on metabolic phenotypes
is still possible if no more than one instrument is invalid, without knowing exactly which of
the four is invalid. We also show conditions for identification when the 50% threshold may
not hold.
Second, we develop a fast `1 estimation procedure to estimate the causal effect of the
exposure on the outcome in the presence of possibly invalid instruments. The procedure has
provable theoretical guarantees on estimation performance and is computationally as fast
as ordinary least squares. The procedure is implemented and available on CRAN as an R
package sisVIVE, which stands for Some Invalid Some Valid IV Estimator.
Third, we conduct a simulation study that compares our method to two-stage least
squares (TSLS), the most popular estimation procedure in IV estimation. We show that our
procedure dominates TSLS when the instruments may be invalid. We also conduct a real
MR study concerning the effect of BMI on health-related quality of life (HRQL) measure
using our new method.

6

2

CAUSAL MODEL AND INSTRUMENTAL
VARIABLES

2.1

Notation

To define valid instruments, the potential outcomes approach (Neyman 1923; Rubin 1974)
for instruments laid out in Holland (1988) is used. For each individual i ∈ {1, . . . , n},
(d,z)

let Yi

∈ R be the potential outcome if the individual were to have exposure d ∈ R and
(z)

instruments z ∈ RL . Let Di

∈ R be the potential exposure if the individual had instruments
(d,z)

z ∈ RL . For each individual, only one possible realization of Yi

(z)

and Di

is observed,

denoted as Yi and Di , respectively, based on his observed instrument values Zi. ∈ RL and
exposure Di . In total, n sets of outcome, exposure, and instruments, denoted as (Yi , Di , Zi. ),
are observed in an i.i.d. fashion.
We denote Y = (Y1 , . . . , Yn ) to be an n-dimensional vector of observed outcomes, D =
(D1 , . . . , Dn ) to be an n-dimensional vector of observed exposures, and Z to be a n by L
matrix of instruments where row i consists of Zi. .
For any vector α ∈ RL , let αj denote the jth element of α. Let kαk1 , kαk2 , and kαk∞
be the usual 1, 2 and ∞-norms, respectively. Let kαk0 denote the 0-norm, i.e. the number
of non-zero elements in α. The support of α, denoted as supp(α) ⊆ {1, . . . , L}, is defined
as the set containing the non-zero elements of the vector α, i.e. j ∈ supp(α) if and only if
αj 6= 0. A vector α is called s-sparse if it has no more than s non-zero entries. Also, for a
vector α ∈ RL and set A ⊆ {1, . . . , L}, we denote αA ∈ RL to be the vector where all the
elements except whose indices are in A are zero.
For any n by L matrix M ∈ Rn×L , we denote the (i, j) element of matrix M as Mij ,
the ith row as Mi. , and the jth column as M.j . Let MT be the transpose of M. Let
PM be the n by n orthogonal projection matrix onto the column space of M, specifically
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PM = M(MT M)−1 MT ; it is assumed that MT M has a proper inverse, unless otherwise
noted. Let PM⊥ be the residual projection matrix, specifically PM⊥ = I − PM where I is an
n by n identity matrix.
For any sets A ⊆ {1, . . . , L}, we denote AC to be the complement of set A. Also, we
denote |A| to be the cardinality of set A.

2.2

Model

We consider the Additive LInear, Constant Effects (ALICE) model of Holland (1988) and
extend it to allow for multiple valid and possibly invalid instruments as in Small (2007).
Let d0 , d ∈ R be possible values of the exposure and z0 , z ∈ RL be possible values of the
(0,0)

instruments. Let i = Yi

(0,0)

− E[Yi

|Zi. ] and the collection of i be denoted as  =

(1 , . . . , n ). Suppose we have the following potential outcomes model for the outcome
(d0 ,z0 )

(d,z)

Yi

− Yi
(0,0)

E(Yi

= (z0 − z)T φ∗ + (d0 − d)β ∗

(1)

|Zi. ) = ZTi. ψ ∗

(2)

where φ∗ , ψ ∗ ∈ RL , and β ∗ ∈ R are unknown parameters. In equation (1), the parameter β ∗
represents the causal parameter of interest, the causal effect on the outcome of changing the
exposure by one unit. Also in equation (1), the parameter φ∗ represents the direct effect of
the instruments on the outcome; changing instruments from z0 to z results in a direct effect
on the outcome of (z0 − z)T φ∗ . In equation (2), the parameter ψ ∗ represents the confounders
that affect the instrument and the outcome. In particular, without any confounders, there
(0,0)

should not be any relationship between the instruments Zi. and the potential outcome Yi

.

Instead, in equation (2), they are related via ψ ∗ .
Let α∗ = φ∗ + ψ ∗ . When we combine equations (1) and (2) along with the definition of
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i , we have the observed data model

Yi = ZTi. α∗ + Di β ∗ + i ,

E(i |Zi. ) = 0

(3)

We make the following remarks regarding the model (3). First, the model can include
exogenous measured covariates, say Xi. ∈ Rp which may include the intercept term, and
we can replace the variables Yi , Di , and Zi. with the residuals after regressing them on X
(e.g. replace Y by (I − PX )Y) where X is the n by p matrix of covariates (Wang and Zivot
1998). The results in this paper will hold generally when working with such data that is
transformed by regressing out the effect of X. In the same spirit, the model can be extended
to non-linear models by including appropriate basis transformations of Zi. . However, for
simplicity of exposition, we will focus on a model without any measured covariates or nonlinear terms. We will also assume that Y, D, and the columns of Z are centered, which can
also result from a residual transformation with X containing only the intercept term.
Second, following Heckman and Robb (1985), Björklund and Moffitt (1987), and Small
(2007), we can incorporate heterogeneous effects as follows. Suppose, instead of equation
(1), the potential outcomes model for the outcome is
(d0 ,z0 )

Yi

(d,z)

− Yi

= (z0 − z)T φ∗ + (d0 − d)βi∗

(4)

where β ∗ = E(βi∗ ) is the average effect of the exposure for everyone in the population. Then,
the observed data model can be derived from (4) as follows.

Yi = ZTi. α∗ + Di β ∗ + (βi∗ − β ∗ )Di + i ,

E(i |Zi. ) = 0

(5)

If (βi∗ − β ∗ ) is independent of Di given Zi. , the heterogeneous model in (5) is identical to
model (3) and our result for Theorem 1 in Section 3.1 hold. Also, as Small (2007) notes
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in page 1055, the assumption that (βi∗ − β ∗ ) is independent of Di given Zi. is equivalent to
that “units do not select their treatment levels Di given Zi. based on the gains they would
experience from treatment Di given Zi. .” If this assumption is violated, different groups of
people will have different treatment effects, which in turn would lead to possibly non-zero α∗
(see Angrist and Imbens (1995) and Small (2007) for details). For simplicity of exposition,
we’ll focus on a model with constant linear effect β ∗ .

2.3

Definition of Valid Instruments

Based on the observed model in (3), the parameter α∗ combines both the direct effect,
(0,0)

represented by φ∗ , and the effect of confounders on the Zi. and Yi

relationship, represented

by ψ ∗ . If there is no direct effect and no effect of the confounders, then α∗ = 0. Hence,
the value of α∗ captures the notion of valid and invalid instruments. The definition below
formalizes this idea:
Definition 1. Suppose we have the models in (1) -(3) with L instruments. We say instrument
j ∈ {1, . . . , L} is valid if αj∗ = 0 and invalid if αj∗ 6= 0.
Definition 1 distinguishes valid and invalid instruments based on supp(α∗ ), the support
of α∗ . If instrument j = 1, . . . , L is not in the support, it is valid. If the instrument is in
the support of α∗ , it is invalid. Consequently, not knowing which instruments are valid and
invalid directly translates to not knowing the support of α∗ in model (3).
In the case of only one instrument (i.e. L = 1), Definition 1 of a valid instrument matches
with the informal definition (A2) and (A3) in the Introduction and the formal definition in
(d,z)

Holland (1988). Specifically, the notion of exclusion restriction (A2), Yi

(d,z 0 )

= Yi

for all

z, z 0 ∈ R is equivalent to the parameter φ∗ in equation (1) being zero. Also, the assumption
(d,z)

of no unmeasured confounding of the IV-outcome relationship (A3) where Yi

(z)

and Di are

independent of Zi for all d, z ∈ R, is encoded by ψ ∗ in (2) being zero. Hence, φ∗ = ψ ∗ = 0,
which implies α∗ = 0 and a valid IV in Holland (1988) is also a valid IV in our definition.
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Also, for one instrument, our model and definition is a special case of the definition of valid
instrument discussed in Angrist et al. (1996) where our model assumes an additive, linear,
and constant treatment effect β ∗ .
For more than one instruments (i.e. L > 1), our model (1)-(3) and definition of valid
IVs can be viewed as a generalization of Holland (1988). It is important to note that in this
generalization, Definition 1 defines the validity of an instrument j in the context of the set
of instruments {1, . . . , L} being considered. Specifically, an instrument j could be valid in
the context of the set {1, . . . , L} (i.e. αj∗ = 0), but invalid if considered alone because Z.j
may be associated with or causally affect another IV Z.j 0 , j 6= j 0 where αj∗0 6= 0.

3
3.1

ESTIMATION OF CAUSAL EFFECT

Identifiability of Model

We first address whether the model in equation (3) is identifiable, that is whether we can
estimate the unknown parameters if we were given infinite data, even without any knowledge
about which instruments are valid and invalid. We begin by making the assumptions.
(a) E(ZT Z) is full rank;
(b) For E(ZT D) = E(ZT Z)γ ∗ , the components of γ ∗ are all not equal to zero, i.e. γj∗ 6= 0
for j = 1, . . . , L.
Assumption (a) states that the matrix of instruments Z is full rank, a common assumption
in the instrumental variables literature (Wooldridge 2010). Assumption (b) states that the
instruments are associated with the exposure, akin to assumption (A1), that the instruments
are relevant to the exposure; note that there does not need to be a causal relationship between
the instrument Z and the exposure D, just an association (Hernán and Robins 2006; Didelez
and Sheehan 2007; Glymour et al. 2012). As one reviewer remarked, assumption (b) requires
11

that all L instruments are related to the exposure, γj∗ 6= 0 for all j. If we have instruments
that are not relevant to the exposure, γj∗ = 0, we can exclude them from further analysis
and concentrate only on those instruments that affect the exposure.
Now, the model in (3) implies the following moment condition.

E(ZT (Y − Zα∗ − Dβ ∗ )) = 0

(6)

Suppose the assumptions (a) and (b) hold. Then, the moment equation in equation (6)
simplifies to
Γ∗ = α∗ + γ ∗ β ∗

(7)

where Γ∗ = E(ZT Z)−1 E(ZT Y). Since both Γ∗ and γ ∗ , defined by (b), can be identified by
their moments based on observed data E(ZT Z)−1 E(ZT Y) and E(ZT Z)−1 E(ZT D), respectively, α∗ and β ∗ are identified if we can find a bijective mapping between α∗ , β ∗ and Γ∗ , γ ∗ ,
i.e. a unique solution α∗ , β ∗ given Γ∗ , γ ∗ .
If we know exactly which instruments are invalid A∗ = supp(α∗ ) = {j : αj∗ 6= 0} and
hence, know the set of valid instruments (A∗ )C = {j : αj∗ = 0}, equation (7) becomes
∗
∗
∗
∗
∗
α(A∗ )C + γ(A
∗ )C β = γ(A∗ )C β = Γ(A∗ )C

There is a unique β ∗ so long as |(A∗ )C | > 0, or there is at least one known valid instrument.
This is a special case of the classic identification result for linear simultaneous equation
models (Koopmans et al. 1950).
If we know that there is a valid instrument, but are not sure of the identity of the valid
instrument(s), then a unique solution to (7) and hence, identification, is not guaranteed. For
example, let there be four instruments, L = 4 with γ ∗ = (1, 2, 3, 4) and Γ∗ = (1, 2, 3, 8).
Then, depending on the set of valid instruments (A∗ )C , which is unknown, we have two
different β ∗ that satisfy equation (7). If the set of valid instruments (A∗ )C is (A∗ )C =
12

∗
∗
{1, 2, 3}, we have γ(A
= Γ∗(A∗ )C and β ∗ = 1. However, if the set of valid instruments
∗ )C β

is (A∗ )C = {4}, β ∗ = 2. Without knowing exactly which (A∗ )C is the true set of valid
instruments, we can’t choose between the two β ∗ s and hence, there is not a unique solution
to (7).
But, suppose we impose constraints on A∗ . Specifically, suppose the number of invalid
instruments, s = |A∗ |, has to be less than some number U , s < U , without knowing which
instruments are invalid or knowing exactly the number of invalid instruments. For example,
geneticists may have a rough idea on the maximum number of invalid instruments, U , but not
know exactly the number of invalid instruments nor do they know exactly which instruments
are invalid. Note that this condition of knowing the maximum number of invalid instruments
is a much weaker requirement than what is traditionally required in IV and MR literature
where one must know exactly which instruments are invalid, i.e. know exactly the set A∗ ;
here, we only need an upper bound on the cardinality of A∗ . Under the weaker condition
s < U , a unique solution to (7) can exist and this is stated in Theorem 1.
Theorem 1 (Uniqueness of Solution). Suppose we assume assumptions (a) and (b) and the
modeling assumption (3). Let s ∈ {0, 1, . . . , L} with s < U where U = 1, . . . , L. Consider
all sets Cm ⊆ {1, . . . , L}, m = 1, . . . , M of size |Cm | = L − U + 1 with the property
γj∗ qm = Γ∗j

j ∈ Cm

where qm is a constant. There is a unique solution α∗ and β ∗ to (7) if and only if qm = qm0
for all m, m0 ∈ {1, . . . , M }.
To understand Theorem 1, note that if the valid instruments are those in the set Cm ,
then the causal effect β ∗ = qm . Theorem 1 says that β ∗ is identified as long as there are
not two subsets of the instruments of cardinality L − U + 1 that give internally consistent
estimates of β ∗ (i.e. all instruments in each subset give the same estimate of β ∗ ), but are
13

externally inconsistent (i.e. the estimates of β ∗ from the two subsets are different). We call
the property in Theorem 1 that there is a unique solution to α∗ and β ∗ to (7) if and only if
qm = qm0 for all m, m0 ∈ {1, . . . , M } the consistency criterion. We thank Jack Bowden for
his insight and suggestions on terminology for interpreting Theorem 1.
As an example of applying Theorem 1, consider our numerical example above with
γ ∗ = (1, 2, 3, 4) and Γ∗ = (1, 2, 3, 8) and U = 3. Then, by Theorem 1 we have 3 sets
C1 = {1, 2}, C2 = {1, 3}, C3 = {2, 3} with q1 = q2 = q3 = 1. Hence, γ ∗ and Γ∗ satisfy the
consistency criterion of Theorem 1 and we have a unique solution α∗ and β ∗ to (7). In contrast, if γ ∗ = (1, 2, 3, 4) and Γ∗ = (1, 2, 6, 8), we would have two sets C1 = {1, 2}, C2 = {3, 4}
with q1 = 1 and q2 = 2, respectively. These γ ∗ and Γ∗ do not satisfy the consistency criterion
of Theorem 1 because q1 6= q2 and there are no unique solutions α∗ and β ∗ to (7). Further
discussion of this particular example is discussed in the Supplementary Materials along with
discussion of the implications of Theorem 1 when the additional linearity and normality assumptions of the classical linear simultaneous/structural equation model (Koopmans et al.
1950) are considered.
Checking the consistency criterion can be computationally difficult, especially if U is

L
possible subsets of {1, . . . , L} and the constants qm
large; it requires looking at L−U
+1
associated with Γ∗ and γ ∗ . Corollary 1 says that the consistency criterion is automatically

satisfied if U ≤ L/2 (i.e. if 50% of the total candidate of L instruments are invalid) regardless
of the values of γ ∗ and Γ∗ .
Corollary 1. If U ≤ L/2, there is always a unique solution to (7)
In addition to the computational benefits, compared to Theorem 1, Corollary 1 is simpler
to interpret. For example, for a geneticist, without knowing the entire biology of genetic
instruments, specifically knowing which instruments are valid and invalid, as long as the
number of invalid instruments is less than 50% of the total instruments, then the geneticist
can rest assured that the parameters can always be identified. If this is not the case, the
14

geneticist can always check the consistency criterion stated in Theorem 1.
We would like to mention two final points about Theorem 1. First, Theorem 1 is a
statement about uniqueness of solutions for the parameters α∗ , and β ∗ in equation (7). A
natural question to ask is whether the uniqueness is guaranteed for just β ∗ , the causal effect
of interest, at the expense of non-uniqueness of α∗ . In the proof of Theorem 1, we show
that this cannot be the case. Specifically, regardless of the condition on s, the parameter
β ∗ is a unique solution to (7) if and only if the parameter α∗ is a unique solution to (7).
Second, Theorem 1 supposes the existences of the sets Cm and proceeds to compare their
corresponding qm . However, one may ask whether these sets Cm even exist in the first place.
In the proof of Theorem 1, we provide a rigorous argument that, indeed, under model (3)
and s < U , at least one set Cm has to exist.

3.2

Estimation of the Causal Effect of Exposure on Outcome

Given the model (3) and s < U , Theorem 1 lays out the sufficient and necessary condition for
finding a unique solution to the moment equation (6). Specifically, if the model is identified,
the moment equation (6) is zero at exactly one value, the true value of α∗ and β ∗ . Naturally
then, a method to estimate the one true value is to find the values of α∗ and β ∗ that minimize
(6) subject to the parameter constraint that s < U . Formally, we can write this estimation
strategy as
argmin
α,β

1
kPZ (Y − Zα − Dβ)k22 ,
2

s.t. ||α||0 < U

(8)

where ||α||0 is the number of non-zero entries of α and by Definition 1, s = ||α||0 . Equation
(8) is similar to the moment selection criterion (MSC) in Andrews (1999). However, both the
moment selection criterion in Andrews (1999) and (8) are computationally infeasible in the
sense that both require going through all subsets of size less than U and this type of problem
has been shown to be NP-hard (Natarajan 1995). Instead, a computationally tractable
version of estimation strategies like (8) has been proposed in the literature using a convex
15

surrogate of the `0 norm (Candes and Tao 2005; Tropp 2006; Donoho 2006). Specifically,
the computationally feasible version of the estimation strategy in (8) can be written as

argmin
α,β

1
kPZ (Y − Zα − Dβ)k22 ,
2

s.t. ||α||1 ≤ t

(9)

where the `0 norm is replaced by the convex norm `1 and U is replaced by a user-specified
tuning parameter t > 0. In this paper, we propose the equivalent Lagrangian form as our
estimator of the causal effect, called some invalid some valid IV estimator, or sisVIVE, as
follows
(α̂λ , β̂λ ) ∈ argmin
α,β

1
kPZ (Y − Zα − Dβ)k22 + λkαk1
2

(10)

for some tuning parameter λ > 0 where λ corresponds to t in (9). If λ = 0 in (10), then (10)
is the popular two stage least squares (TSLS) estimator, which is equivalent to the GMM
estimator when the  are assumed to be homoscedastic (Hansen 1982). Hence, sisVIVE can
be viewed as a generalization of TSLS or GMM.
sisVIVE also bears some resemblance to the traditional `1 penalization procedure, in
particular the Lasso (Tibshirani 1996) or the recent `1 penalty procedures in IV estimation by
Gautier and Tsybakov (2011) and Belloni et al. (2012). However, there are a few important
differences. First, with regards to traditional Lasso and the procedure proposed by Gautier
and Tsybakov (2011), our procedure in (10) only penalizes α∗ . The estimator (10) does not
penalize β ∗ , the causal effect of the exposure on the outcome, because the causal effect may
be far from zero. In contrast, the prior works we mentioned penalize all the parameters in the
model. Second, the traditional Lasso only considers regression with all exogenous regressors,
which are regressors that are assumed to be independent of the error term or assumed to be
fixed. The regressors in our model (3) are not all exogenous; specifically, model (3) contains
one random endogenous variable, Di , which is dependent on the error term. Third, Gautier
and Tsybakov (2011) and Belloni et al. (2012) assume that either all the L instruments are
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valid or we know exactly which subset of them are valid. In contrast, our procedure does
not assume this.
Finally, a careful reader may have recognized that there may be multiple minimizers to
the equation (10), specifically β̂λ , because ||α||1 is not strictly convex and hence, we use the
set notation instead of the equality sign in (10). This might seem to be a concern as there
are multiple estimates of β ∗ . However, as we will show in Section 3.4, all minimizers of (10)
are close to the true values β ∗ . Also, if the entries of the matrix PD̂⊥ Z where D̂ = PZ D
(i.e. the predicted value of the exposure given the instruments) are drawn from a continuous
distribution, then the solution to (10) is unique (Tibshirani 2013).
Without loss of generality, we assume that the columns of Z are scaled to unit length. This
allows all L instruments to have identical units so no columns of Z gets unfairly penalized
by the penalty term in (10) simply due to their original units.

3.3

Choice of λ

Like many penalization procedures, the choice of the tuning parameter λ affects the performance of the estimation procedure and this is certainly the case with sisVIVE. High values
of λ force heavy penalization on α, which will put most elements of α̂λ to zero and most
instruments will be estimated as valid instruments. In contrast, low values of λ will put few
elements of α̂λ to zero and most instruments will be estimated as invalid instruments. In
short, the optimal choice of λ depends on knowing the exact number of invalid and valid
instruments, something not implied by the condition s < U .
In practice, cross validation is a popular data-driven method to choose λ. In the same
spirit, we use a K-fold cross validation where we minimize the estimating equation ||PZ (Y −
Zα − Dβ)||2 instead of the predictive error ||(Y − Zα − Dβ)||2 . We minimize the estimating
equation instead of the predictive error since the parameter of interest is the causal effect β ∗
that sets the expected value of the estimating equation to zero (see equation (6), Sections
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3.1 and 3.2). We use the “one standard error” rule used in most cross-validation procedures
(Hastie et al. 2009) and choose the smallest λ that is no more than one standard error
above the minimum of the estimating equation. In Section 4, we discuss the performance
of β̂λcv , where λcv is the cross-validated λ based on the estimating equation through various
simulation studies. Also, in the Supplementary Materials, we discuss another method of
choosing λ, in particular, choosing λ based on the theoretical guidance from Theorem 2
and Corollary 2. In short, the Supplementary Materials show that for better estimation
performance of β̂λ , it is important not to incorrectly set invalid IVs to be valid (i.e. let α̂j to
be zero when the true αj∗ is not zero), while the reverse is not as important. This observation
argues for choosing λ that tends to set relatively few elements of α̂λ to be zero and in the
Supplementary Materials, we demonstrate that cross validation achieves this goal in a wide
variety of settings.

3.4

Estimation Performance

How well does sisVIVE estimate the causal effect β ∗ ? In order to analyze the performance
of sisVIVE, we first introduce some basic notations and definitions.
Definition 2. For any matrix M, the upper and lower restricted isometry property (RIP)
constants of order k, denoted as δk+ (M) and δk− (M) respectively, are the smallest δk+ (M) and
largest δk− (M) such that
δk− (M)kαk22 ≤ kMαk22 ≤ δk+ (M)kαk22

(11)

holds for all k-sparse vectors α.
RIP conditions have been widely used in the literature on compressed sensing and highdimensional linear regression. See Cai and Zhang (2013) and the references therein. The
following theorem characterizes the performance of sisVIVE in finite samples using the RIP
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conditions. Note that this characterizes all the minimizers β̂λ from sisVIVE in (10).
Theorem 2 (Estimation performance of sisVIVE). Suppose we have the model given in (3).
+
−
+
(Z), δ2s
(Z), δ2s
(PD̂ Z) be defined as
Let D̂ = PZ D. Let the restricted isometry constants δ2s

in (11), where s is the number of invalid instruments. Suppose

−
+
+
2δ2s
(Z) > δ2s
(Z) + 2δ2s
(PD̂ Z)

(12)

holds, then the estimate β̂λ given by (10) with tuning parameter λ ≥ 3kZT PD̂⊥ k∞ has the
following performance guarantee

|β̂λ − β ∗ | ≤

|D̂T |
kD̂k22

+

1
kD̂k2

!
√ p +
(4/3 5)λ sδ2s
(PD̂ Z)
.
−
+
+
2δ2s
(Z) − δ2s
(Z) − 2δ2s
(PD̂ Z)

(13)

−
+
+
(Z), δ2s
(Z), and δ2s
(PD̂ Z). Unfortunately,
Condition (12) includes the RIP constants, δ2s

these RIP constants in (12) are difficult to evaluate. Hence, in some applications, it is more
convenient to use a slightly stronger but much simpler and interpretable condition called
the “mutual incoherence property” (MIP). Specifically, let D̂ = PZ D and kZ.j k2 = 1 for all
j = 1, . . . , L. Define the constants µ and ρ as

µ = max |ZT.i Z.j | and ρ = max |D̂T Z.j |/kD̂k2 .
i6=j

j

(14)

First, the constant µ measures the maximum correlation between any two columns of the
matrix of instruments Z. This is related to Assumption (a) in Section 3.1 where a full rank
Z means the columns of Z are linearly independent. In fact, if µ < 1/(L − 1), Z is full rank.
Second, the constant ρ measures the maximum strength of individual instruments. A high ρ
doesn’t necessarily imply that all L instruments are individually strong; it just implies that
one of the L instruments is strong (i.e. has a high correlation to D); it’s possible that the
19

rest of the L − 1 instruments are weak. This notion of strength by ρ is slightly different than
the concentration parameter, which measures the overall strength of all the L instruments
(see Section 4 for details). Also, ρ stands in contrast to Condition (b) in Theorem 1 which
looks at the individual values of γj , j = 1, . . . , L, instead of the maximum of γj s.
Given the two MIP constants µ and ρ, we have the following result on estimation performance. Like Theorem 2, Corollary 2 characterizes all the minimizers β̂λ from sisVIVE in
(10).
Corollary 2 (Estimation performance of sisVIVE under MIP). Let the MIP constants µ
and ρ be given in (14). If the number of invalid instruments, s, satisfies

s < min(

1
1
,
)
12µ 10ρ2

(15)

the estimate β̂λ given by (10) with tuning parameter λ ≥ 3kZT PD̂⊥ k∞ has the following
performance guarantee

|β̂λ − β ∗ | ≤

|D̂T |
kD̂k22

+

1
kD̂k2

!
√
4 105/9λsρ
.
1 − s(5ρ2 + 6µ)

(16)

We make the following remarks. First, in the Supplementary Materials, we show the
condition in equation (15) directly implies the condition in equation (11). We also provide
an example of a matrix of instruments Z where the RIP condition is satisfied, but the MIP
condition is not satisfied. Second, the constraint on the number of invalid instruments, s,
in Corollary 2 is strict, but is required to precisely characterize the bound on estimation
performance. As two reviewers pointed out, if the instruments are even slightly correlated
at µ = 0.1, s < 10/12, no invalid instruments are allowed, and Corollary 2 is not useful in
characterizing the performance of sisVIVE. In Section 4 and in the Supplementary Materials,
we study the behavior of sisVIVE when this constraint in (15) may not hold. Third, in the
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case where all the instruments are uncorrelated with each other so that µ = 0, a small ρ
provides a less restrictive upper bound on s. At first glance, this may be counterintuitive
since a small ρ implies that all the instruments’ individual correlation to the exposure is
weak and, therefore, having weak instruments allow one to have more invalid instruments.
However, we note that the denominator of the bound (16), specifically kD̂k22 is a function
of the correlation of the instruments, and having a small ρ would translate to having a
small kD̂k22 . Hence, even though the condition (15) allows for more invalid instruments,
the upper bound (16) becomes worse and our estimator β̂λ will be far from β ∗ . Finally,
we emphasize that the conditions in both Theorem 2 and Corollary 2 are sufficient, but
not necessary conditions for the performance bounds to hold. In particular, a violation of
these conditions does not imply that sisVIVE will perform badly (see Section 4 and the
Supplementary Materials).

3.5

Fast Numerical Algorithm

In addition to the theoretical guarantees on estimation performance, in practice, a fast,
scalable numerical algorithm for estimation is desirable, especially for MR where genetic
data can be large. Theorem 3 outlines a two-step numerical method whose solution is
identical to sisVIVE in (10), but is as fast as ordinary least squares.
Theorem 3 (Fast two-step numerical algorithm). Let PD̂ be the projection matrix onto the
vector D̂ and PD̂⊥ = I − PD̂ . We propose the two-step algorithm as follows.
Step 1: For a given λ > 0, solve:

α̂λ ∈ argmin
α

1
||P ⊥ PZ Y − PD̂⊥ Zα||22 + λ||α||1
2 D̂
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Step 2: Use α̂λ from Step 1 to estimate β̂λ by

β̂λ =

D̂T (Y − Zα̂λ )
||D̂||22

The solution to the two-step algorithm is identical to the solution to sisVIVE in (10)
In the two-step algorithm, step 1 is the standard Lasso problem with outcome PD̂⊥ PZ Y
and PD̂⊥ Z; remember, sisVIVE in (10) is not the standard Lasso problem as discussed in
Section 3.2. Fast algorithms for the Lasso exist, most notably LARS (Efron et al. 2004). In
fact, LARS is able to solve α̂λ for all values of λ > 0 at the same computational efficiency
as ordinary least squares. Step 2 is also numerically efficient, requiring a simple dot product
operation between D̂ and Y − Zα̂λ . Thus, the proposed two-step algorithm is, practically
speaking, as fast as ordinary least squares. Best of all, the estimate from this two-step
algorithm is identical to sisVIVE.

4

SIMULATION STUDY

We conduct various simulation studies to study the estimation performance, measured by |β̂−
β ∗ |, for different methods. Specifically, we compare sisVIVE with TSLS, the most popular
estimator in IV and MR, and ordinary least squares (OLS) under various settings that vary
the instruments’ absolute/overall and relative strength, their validity and correlation among
each other, and endogeneity.
Let there be n = 2000 individuals and L = 10 potential candidate instruments. The
observations (Yi , Di , Zi. ), i = 1, . . . , n are generated by
∗

Yi = π +

ZTi. α∗

∗

+ Di β + i

Di = γ0∗ + ZTi. γ ∗ + ξi


 
  
∗
i  iid 0  1 σξ 
,   ∼ N   , 

∗
ξi
σξ
1
0
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where Zi. is drawn from a multivariate normal with mean 0 and covariance matrix where
the diagonals are all one. Throughout the simulation, the parameters π ∗ , β ∗ , and γ0∗ are
∗
fixed. However, we vary (i) the endogeneity parameter σξ
, (ii) the direct effect parameter

α∗ = (1, 1, . . . , 0, 0) where we change s in kα∗ k0 = s, (iii) the pairwise correlation between
instruments, i.e. µ in equation (14), (iv) the absolute/overall strength of instruments, and
(v) the relative strength of instruments, the latter two by changing the parameter γ ∗ .
∗
In particular, for (i), we vary σξ
from 0 to 0.9. For (ii), we vary s from 0 to 9. For (iii), we

set µ at four different values, 0, 0.25, 0.5, and 0.75, by setting all the off-diagonal elements of
the covariance matrix of Zi. to this value. For (iv), we vary the absolute/overall instrument
strength by the concentration parameter. The concentration parameter is a popular measure
for instrument strength; high values of the concentration parameter indicate the overall
strength of all L instruments are strong and vice versa. The concentration parameter is also
the population value of the first stage F statistic for the instruments when the exposure is
regressed on them; this first stage F statistic is often used to check instrument strength (Stock
et al. 2002). Based on Table 1 in Stock et al. (2002), a set of instruments with a concentration
parameter (scaled by the number of valid instruments) of around 10 is considered weak in
the absolute/overall sense and instruments with a concentration parameter (scaled by the
number of valid instruments) of around 100 is considered strong in the absolute/overall sense.
Finally for (v), we vary the relative instrument strength by changing the individual entries of
the vector γ ∗ while keeping the concentration parameter fixed. Specifically, for a particular
concentration parameter, we consider instruments to have equal relative strength if γj∗ = γk∗
for all j 6= k and variable relative strength if γj∗ = 2 ∗ γk∗ for various values of j 6= k.
For each simulation setting, we repeat the simulation 1000 times. For each repetition,
we compute sisVIVE’s estimate of the causal effect, β̂λ , where λ is chosen by 10-fold cross
validation outlined in Section 3.3. We also compute estimates from TSLS and OLS. For
TSLS, we run two types of TSLS. First, we run the “naive” TSLS as if all the instruments
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are valid. This is quite common in MR studies where all the instruments are assumed to
be valid and the causal estimate is computed using TSLS. When some of the instruments
are in fact invalid, naive TSLS should give biased estimates. Second, we run TSLS as if we
knew exactly which instruments are valid, i.e. the “oracle” TSLS. Specifically, we use the
knowledge of the support of α∗ and run TSLS controlling for the invalid instruments that are
in the support of α∗ as covariates. Finally, we run OLS with Z and D as our regressors and
Y as our outcome. We expect OLS to perform poorly when there is substantial endogeneity
by D since OLS cannot control for endogenous variables. But, OLS should be more efficient
than IV methods if there is no endogeneity (Richardson and Wu 1971).
Figure 2 shows the estimation error when endogeneity is varied. The number of invalid
instruments is fixed at s = 3 and we consider 16 different sets of instruments based on
their absolute and relative strength as well as their pairwise correlations. For example, the
top lefthand plot of Figure 2 corresponds to instruments whose overall strength is strong
(i.e. scaled concentration parameter is around 100) , their relative strength is equal (i.e.
γj∗ are identical for all j = 1, . . . , L), and their pairwise correlations are 0. In contrast, the
bottom right plot of Figure 2 corresponds to instruments whose their overall strength is weak
(i.e. scaled concentration parameter is around 10), their relative strength is variable (i.e.
γj∗ = 2 ∗ γk∗ for j 6= k) and their pairwise correlations are equal to 0.75.
As expected, OLS dominates naive TSLS, oracle TSLS, and sisVIVE when the endogeneity is small and close to zero, with the dominance being greater for weak instruments.
Once there is a sufficient amount of endogeneity, oracle TSLS, which knows exactly which
instruments are valid and invalid, does best. However, sisVIVE, which is a feasible rather
than infeasible oracle estimator, is close to the oracle TSLS; the gap between oracle TSLS
and sisVIVE gets larger as the instruments’ absolute strength gets weaker. Regardless of
instrument strength, naive TSLS, which assumes all the L instruments are valid, has a high
error since it cannot take into account the bias introduced by invalid instruments.
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Figure 2: Simulation Study of Estimation Performance Varying Endogeneity. There are ten
(L = 10) instruments. Each line represents median absolute estimation error (|β ∗ − β̂|) after
1000 simulations. We fix the number of invalid instruments to s = 3. Each column in the
plot corresponds to a different variation of instruments’ absolute and relative strength. There
are two types of absolute strengths, “Strong” and “Weak”, measured by the concentration
parameter. There are two types of relative strengths, “Equal” and “Variable”, measured by
varying γ ∗ while holding the absolute strength (i.e. concentration parameter) fixed. Each
row corresponds to the maximum correlation between instruments.
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Figure 3 shows the estimation error when the number of invalid instruments is varied. The
∗
endogeneity, σξ
, is fixed at 0.8. Like Figure 2, we consider the same 16 sets of instruments.

We first see that at s = 0, i.e. when there are no invalid instruments, sisVIVE’s performance
is nearly identical to naive and oracle TSLS. However, sisVIVE does not use the knowledge
that one knows exactly which instruments are valid while the two TSLS estimators do. Also,
sisVIVE’s performance degrades slightly for instruments with weak absolute strength when
the correlation between instruments increases.
When s < L/2 = 5, sisVIVE’s performance is comparable to oracle TSLS and better than
naive TSLS. However, for instruments with weak absolute strength, sisVIVE does slightly
worse compared to the oracle TSLS than for instruments with strong absolute strength. Once
we reach the identification boundary in Corollary 1, s < L/2 = 5, sisVIVE’s performance
becomes similar to naive TSLS. This is the case regardless of the instruments’ absolute and
relative strength. Finally, for any s, oracle TSLS performs much better than all the other
estimators.
Also, in all 16 sets of instruments, we compute the ρ and µ found in the condition for
Corollary 2 from the simulated data and this is detailed in the Supplementary Materials. For
example, the top lefthand plot of Figure 2 has ρ of approximately 0.31 and µ = 0. Based on
this, the upper bound on s in Corollary 2 is 1.04. However, since s = 3 for the simulations in
Figure 2, the condition (15) in Corollary 2 is violated and cannot be used to characterize the
behavior of sisVIVE. Regardless, in our simulation study presented in this Section, sisVIVE
performs just as well as the oracle TSLS.
In the Supplementary Materials, we expand the simulation study to cover different types
of instrument strength, correlation structure between instruments, and total number of potential instruments. We also explore different metrics of error, such as the proportion of
correctly selected valid instruments and invalid instruments, to analyze the relationship between these proportion-based error metrics and the median bias error metric used in this
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Figure 3: Simulation Study of Estimation Performance Varying the Number of Invalid Instruments (s). There are ten (L = 10) instruments. Each line represents median absolute
∗
∗
estimation error (|β ∗ − β̂|) after 1000 simulations. We fix the endogeneity σξ
to σξ
= 0.8.
Each column in the plot corresponds to a different variation of instruments’ absolute and
relative strength. There are two types of absolute strengths, “Strong” and “Weak”, measured by the concentration parameter. There are two types of relative strengths, “Equal”
and “Variable”, measured by varying γ ∗ while holding the absolute strength fixed. Each row
corresponds to maximum correlation between instruments.
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Section. In addition, we also compute the conditions for Corollary 2, specifically ρ, µ, and
λ required to achieve the performance bound. The Supplementary Materials show that
in every case considered, sisVIVE performs no worse than the next best alternative, naive
TSLS. In fact, in most cases, sisVIVE beats naive TSLS and performs similarly to the oracle
TSLS. The only case where sisVIVE’s performance deviated greatly from the oracle TSLS
was when the invalid instruments were weaker than the valid instruments and s = 4. In
addition, the Supplementary Materials show that a good estimate of β ∗ depends strongly
on correctly selecting the invalid instruments more than correctly selecting the valid instruments and choosing λ based on cross validation seems to favor this situation. We also find
that choosing λ based on Corollary 2 leads to a higher λ than one based on cross validation.
Finally, we find that sisVIVE based on λ chosen by cross validation always performed at
least as well as sisVIVE based on λ chosen by Corollary 2. In fact, in most cases, sisVIVE
with a cross-validated λ performs better than sisVIVE with a λ chosen by Corollary 2.
Overall, sisVIVE using a cross-validated λ does much better than naive TSLS, the most
frequently used estimator in MR and IV. In many cases, sisVIVE beats the naive TSLS
and it is comparable to oracle TSLS. The promising simulation results suggest that sisVIVE
should be used whenever there is concern about invalid instruments.

5

DATA ANALYSIS

We demonstrate the potential benefit of using sisVIVE in MR by analyzing the effect of
obesity, the exposure, on health-related quality of life, the outcome. An individual’s quality
of life is the general well-being of the individual; an individual’s health quality of life is the
subset of quality of life related to the individual’s health (Torrance 1987). Previous non-MR
studies by Trakas et al. (2001) and Sach et al. (2007) have shown that there is a negative association between obesity and health-related quality of life. However, a fundamental
difficulty with these studies is that the outcome, health-related quality of life, encompasses
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various factors about the individual, making it difficult to control for all possible confounders
that may affect obesity and health-related quality of life (Cawley and Meyerhoefer 2012).
An MR approach offers the potential of controlling for unmeasured confounders.
For the analysis, we use the data from the Wisconsin Longitudinal Study (WLS), a
well-known longitudinal study that has kept track of American high school graduates from
Wisconsin since 1957. We look at graduates that were reinterviewed in 2003-2005 (Hauser
2005) and who have been genotyped. Similar to another analysis with the WLS genetic data,
we remove individuals with more than 10% missing genotype data (Roetker et al. 2012). Our
analysis of the data set contains n = 3712 individuals with 1913 females and 1799 males
born mostly between 1938 to 1940.
To measure health-related quality of life, we use the Health Utility Index Mark 3 (HUI-3)
which was also used in Trakas et al. (2001). HUI-3 is a composite score of utility between
0 and 1, with 1 indicating highest health state and 0 indicating a health state equivalent to
death; negative utility is possible and indicates that the person is alive, but in a state worse
than death. To measure obesity, we use the body mass index (BMI) and the US National
Institute of Health clinical guidelines (National Institute of Health 1998) that were also used
in Trakas et al. (2001) and Sach et al. (2007) in their analysis. Specifically, we follow Trakas
et al. (2001) and define the exposure by assigning individuals with BMI less than 30 (i.e. not
obese) to be 0, individuals with BMI between 30 and 35 (i.e. obese class I) to be 1, individuals
with BMI between 35 and 40 (i.e. obese class II) to be 2, and individuals with BMI greater
than 40 (i.e. obese class III) to be 3 so that each value of the exposure corresponds to the
increasing obese classes used in Trakas et al. (2001) and the US National Institute of Health
clinical guidelines (National Institute of Health 1998). For instance, exposure value of zero
corresponds to non-obese individuals while exposure value of two corresponds to individuals
in obese class II. Hence, the causal effect of interest is the effect of moving up in the obese
class; specifically β ∗ in model (1) will correspond to the effect of moving up one obese class on
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the HUI-3 index of health-related quality of life. In the Supplementary Materials, we explore
different methods to quantify obesity and the resulting estimates from different methods.
For potential candidate instruments, we use the following single nucleotide polymorphisms (SNPs) in the WLS that have been previously shown to be associated with obesity:
rs1421085, rs1501299, and rs2241766 (see Table 1). rs1421085 is in the FTO gene and it
has been shown to be strongly associated with obesity (Dina et al. 2007; Price et al. 2008).
rs1501299 (i.e. +276G>T) is in the ADIPOQ gene that encodes adiponectin, a protein encoding for lipid metabolism, and has been associated with obesity (Bouatia-Naji et al. 2006;
Yang et al. 2007). Finally, rs2241766 is also in the ADIPOQ gene that has been associated
with obesity (Ukkola et al. 2003; Yang et al. 2003; Beckers et al. 2009). For all the SNPs, we
follow an MR study done by Timpson et al. (2005) and assume an additive model. Although
we have no particular reason to think any of the SNPs is an invalid IV, we are uncertain due
to the lack of complete knowledge about the biological functions of the SNPs, a common
scenario in MR studies. Our sisVIVE estimator will provide a good estimate as long as least
two of the three SNPs are valid IVs.
Table 1. Summary of Instruments
Instruments
Major alleles
rs1421085
1281 (34.5%; TT)
rs1501299
1950 (52.5%; CC)
rs2241766
2956 (79.6%; TT)
rs6265
2437 (65.7%; GG)

in the Data Analysis. MAF stands for minor allele frequency
Heterozygote
Minor alleles
MAF (SE)
1818 (49.0%; CT) 613 (16.5%; CC)
0.39 (0.0057)
1502 (40.5%; AC) 260 (7.0%; AA)
0.24 (0.0049)
719 (19.4%; TG)
37 (1.0%; GG)
0.10 (0.0036)
1112 (30.0%; AG) 163 (4.4%; AA)
0.19 (0.0046)

A simple ordinary least squares analysis estimates that an increase in one obese class is
associated with a 0.052 (SE: 0.0040) decrease in HUI-3 score. The reduced form estimates
along with the first stage F statistics are summarized in the Supplementary Materials.
If we use TSLS, under the operating assumption that all the instruments are valid, the
estimated causal effect is −0.00094 (SE: 0.081), i.e. climbing up one obese class reduces
your health utility quality of life by 0.00094. Our estimator, sisVIVE, which operates only
under the assumption that a proportion of instruments are invalid, estimates −0.00094 as
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the causal effect, which is identical to the estimate by TSLS. Also, sisVIVE does not select
any SNPs as an invalid IV. The overidentifying restrictions test and the implied structural
correlation between Di and the error term are summarized in the Supplementary Materials.
To further validate our method, we include another instrument, rs6265 (i.e. Val66Met).
rs6265 is in the brain-derived neurotrophic factor BDNF gene and has been shown to not only
be associated with BMI (Thorleifsson et al. 2008; Shugart et al. 2009), but also neurological
and cognitive function (Hwang et al. 2006; Rybakowski et al. 2006). Hence, there is some
reason to believe that rs6265 may be pleiotropic; rs6265 may impact obesity, but also affect
health-related quality of life through mechanisms other than obesity. sisVIVE should be able
to pick up on this instrument being invalid in contrast to TSLS, which will always assume
that all the instruments used are valid.
If we use TSLS under the operating assumption that all the four instruments are valid,
the estimated effect is −0.0086 (SE:0.080). sisVIVE, on the other hand, estimates the
causal effect to be −0.0037, which is closer to the estimates when we used three instruments.
sisVIVE also throws out the instrument, rs6265, which we suspect to be invalid. The reduced
form estimates and the overidentifying restrictions test are summarized in the Supplementary
Materials.
In both data analyses, sisVIVE operates under the assumption of possibly invalid instruments, which are typical in MR studies, while TSLS operates under the assumption of all
valid instruments. In the first data analysis where there was no reason to believe that the
instruments were invalid, sisVIVE provides the same answer as TSLS, but without assuming
that all the instruments were valid. In the second data analysis where one instrument was
suspect, sisVIVE removed the suspected instrument. In both cases, sisVIVE was robust to
possibly invalid instruments compared to TSLS.
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6

DISCUSSION

This paper demonstrates that proper estimation of causal effects using the IV method is
possible without knowledge of all the instruments’ validity. Our results show that simply
knowing a proportion of the instrument is valid, without knowing which are valid, is sufficient
and we construct the sisVIVE estimator that dominates the naive TSLS in almost every
aspect while performing similarly to the oracle TSLS. Both the simulation result and data
analysis show that sisVIVE is a robust alternative to TSLS in the presence of possibly invalid
instruments.
Future work could involve generalizing the model considered. In particular, the current
paper discusses a model in which treatment effects are constant. Angrist et al. (1996)
discusses the setting in which the treatment effects are not constant and individuals may
select into treatment based on expected gains from treatment. Then, qm and qm0 in Theorem
1 might not be equal to each other for different sets of valid instruments and Theorem 1
does not apply. It would be useful to understand what sisVIVE is estimating under this
setting of treatment effect heterogeneity. Other useful directions for future work are relaxing
the conditions on Corollary 2 to encompass more invalid instruments s and deriving tests
for identification. Also, we have focused on the applications of our method to Mendelian
randomization. In economic applications, it is also common to have multiple candidate
instruments and be concerned that some proportion of the instruments are invalid (Murray
2006). Our current work demonstrates that instrumental variable estimation is definitely
possible even in the presence of possibly invalid instruments.
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SUPPLEMENTARY MATERIALS

unblind-Proofs: The file contains additional information about the Wisconsin Longitudinal Data, the simulation study, further discussions, and all the technical details,
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including the proofs of Theorems 1, 2, and 3. This is the unblinded version. (pdf file)
blind-Proofs: The file contains additional information about the Wisconsin Longitudinal
Data, the simulation study, further discussions, and all the technical details, including
the proofs of Theorems 1, 2, and 3. This is the blinded version. (pdf file)
Supplementary zip file: The file contains the R-package “sisVIVE” which implements the
method proposed in the paper along with documentation and one technical report on
arXiv and one paper on NBER Working Paper series, both of which are cited in the
main manuscript (GNU zipped file)

References
Andrews, W. K. D. (1999), “Consistent Moment Selection Procedures for Generalized
Method of Moments Estimation,” Econometrica, 67, 543–563.
Angrist, J. D. and Imbens, G. W. (1995), “Two-Stage Least Squares Estimation of Average
Causal Effects in Models With Variable Treatment Intensity,” Journal of the American
Statistical Association, 90, 431–442.
Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996), “Identification of Causal Effects
Using instrumental variables,” Journal of the American Statistical Association, 91, 444455.
Beckers, S., Peeters, A. V., de Freitas, F., Mertens, I. L., Verhulst, S. L., Haentjens, D., Desager, K. N., Van Gaal, L. F., and Van Hul, W. (2009), “Association Study and Mutation
Analysis of Adiponectin Shows Association of Variants in APM1 With Complex Obesity
in Women,” Annals of Human Genetic, 73, 492-501.
Belloni, A., Chen, D., Chernozhukov, V., and Hansen, C. (2012), “Sparse Models and Meth-

33

ods for Optimal Instruments With an Application to Eminent Domain,” Econometrica,
80, 2369-2429.
Björklund, A. and Moffitt, R. (1987), “The Estimation of Wage Gains and Welfare Gains in
Self-Selection Models,” The Review of Economics and Statistics, 69, 42–49.
Bouatia-Naji, N., Meyre, D., Lobbens, S., Séron, K., Fumeron, F., Balkau, B., Heude, B.,
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M. A., Fernández-Tilapa, G., Vences-Velázquez, A., Cruz, M., Salazar-Martı́nez, E., and
Flores-Alfaro, E. (2012), “Haplotypes in the CRP Gene Associated With Increased BMI
and Levels of CRP in Subjects With Type 2 Diabetes or Obesity From Southwestern
Mexico,” Experimental Diabetes Research, vol. 2012, Article ID 982683, 1–7.
Mealli, F. and Pacini, B. (2013) “Using Secondary Outcomes to Sharpen Inference in Randomized Experiments With Noncompliance,” The Journal of the American Statistical Association, 108, 1120-1131.
Murray, M. P. (2006), “Avoiding Invalid Instruments and Coping with Weak Instruments,”
The Journal of Economic Perspectives, 20, 111–132.
Natarajan, B. K. (1995), “Sparse Approximate Solutions to Linear Systems,” SIAM Journal
on Computing, 24, 227–234.
National Institute of Health (1998), “Clinical Guidelines on the Identification, Evaluation,
and Treatment of Overweight and Obesity in Adults: The Evidence Report,” Obesity
Research, 2, 51S–209S.
Neyman, J. (1923), “On the Application of Probability Theory to Agricultural Experiments,”
Statistical Science, 5, 463–480.
Price, R. A., Li, W.-D., and Zhao, H. (2008), “FTO Gene SNPs Associated With Extreme
Obesity in Cases, Controls and Extremely Discordant Sister Pairs,” BMC Medical Genetics, 9, 1–5.
Richardson, D. H. and Wu, D. (1971), “A Note on the Comparison of Ordinary and TwoStage Least Squares Estimators,” Econometrica, 39, 973–981.
Roetker, N. S., Yonker, J. A., Lee, C., Chang, V., Basson, J. J., Roan, C. L., Hauser,
T. S., Hauser, R. M., and Atwood, C. S. (2012), “Multigene Interactions and Prediction
37

of Depression in the Wisconsin Longitudinal Study,” British Medical Journal Open, 2,
e000944.
Rubin, D. B. (1974), “Estimating Causal Effects of Treatments in Randomized and Nonrandomized Studies,” Journal of Educational Psychology, 66, 688–701.
Rybakowski, J. K., Borkowska, A., Skibinska, M., Szczepankiewicz, A., Kapelski, P.,
Leszczynska-rodziewicz, A., Czerski, P. M., and Hauser, J. (2006), “Prefrontal Cognition in Schizophrenia and Bipolar Illness in Relation to Val66Met Polymorphism of the
Brain-derived Neurotrophic Factor Gene,” Psychiatry and Clinical Neurosciences, 60, 70–
76.
Sach, T. H., Barton, G. R., Doherty, M., Muir, K. R., Jenkinson, C., and Avery, A. J.
(2007), “The Relationship Between Body Mass Index and Health-Related Quality of Life:
Comparing the EQ-5D, EuroQol VAS and SF-6D,” International Journal of Obesity, 31,
189–196.
Shugart, Y. Y., Chen, L., Day, I. N., Lewis, S. J., Timpson, N. J., Yuan, W., Abdollahi,
M. R., Ring, S. M., Ebrahim, S., Golding, J., Lawlor, D. A., and Smith, G. D. (2009), “Two
British Women Studies Replicated the Association Between the Val66Met Polymorphism
in the Brain-Derived Neurotrophic Factor (BDNF) and BMI,” European Journal of Human
Genetics, 17, 1050–1055.
Small, D. S. (2007), “Sensitivity Analysis for Instrumental Variables Regression with Overidentifying Restrictions,” Journal of the American Statistical Association, 102, 1049–1058.
Solovieff, N., Cotsapas, C., Lee, P. H., Purcell, S. M., and Smoller, J. W. (2013), “Pleiotropy
in Complex Traits: Challenges and Strategies,” Nature Reviews Genetics, 14, 483–495.
Stock, J. H., Wright, J. H., and Yogo, M. (2002), “A Survey of Weak Instruments and Weak

38

Identification in Generalized Method of Moments,” Journal of Business and Economic
Statistics, 20, 518–520.
Thomas, D. C. and Conti, D. V. (2004), “Commentary: The Concept of ‘Mendelian Randomization’,” International Journal of Epidemiology, 33, 21–25.
Thorleifsson, G., Walters, G. B., Gudbjartsson, D. F., Steinthorsdottir, V., Sulem, P., Helgadottir, A., Styrkarsdottir, U., Gretarsdottir, S., Thorlacius, S., Jonsdottir, I., Jonsdottir, T., Olafsdottir, E. J., Olafsdottir, G. H., Jonsson, T., Jonsson, F., Borch-Johnsen,
K., Hansen, T., Andersen, G., Jorgensen, T., Lauritzen, T., Aben, K. K., Verbeek, A. L.,
Roeleveld, N., Kampman, E., Yanek, L. R., Becker, L. C., Tryggvadottir, L., Rafnar, T.,
Becker, D. M., Gulcher, J., Kiemeney, L. A., Pedersen, O., Kong, A., Thorsteinsdottir,
U., and Stefansson, K. (2008), “Genome-Wide Association Yields New Sequence Variants
at Seven Loci that Associate With Measures of Obesity,” Nature Genetics, 41, 18–24.
Tibshirani, R. (1996), “Regression Shrinkage and Selection via the Lasso,” Journal of the
Royal Statistical Society, Series B, 58, 267–288.
Tibshirani, R. J. (2013), “The Lasso Problem and Uniqueness,” Electronic Journal of Statistics, 7, 1456–1490.
Timpson, N. J., Lawlor, D. A., Harbord, R. M., Gaunt, T. R., Day, I. N., Palmer, L. J.,
Hattersley, A. T., Ebrahim, S., Lowe, G., Rumley, A., and Smith, G. D. (2005), “Creactive Protein and its Role in Metabolic Syndrome: Mendelian Randomisation Study,”
The Lancet, 366, 1954–1959.
Torrance, G. W. (1987), “Utility Approach to Measuring Health-Related Quality of Life,”
Journal of Chronic Disease, 40, 593-600.
Trakas, K., Oh, P. I., Singh, S., Risebrough, N., and Shear, N. H. (2001), “The Health Status

39

of Obese Individuals in Canada,” International Journal of Obesity and Related Metabolic
Disorders: Journal of the International Association for the Study of Obesity, 25, 662–668.
Tropp, J. A. (2006), “Just Relax: Convex Programming Methods for Identifying Sparse
Signals in Noise,” IEEE Transactions on Information Theory, 52, 1030–1051.
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